Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 7/20 | 0.52 |
| ▸ | PTGFR | P43088 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TACR3 | P29371 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601611 | 0.93 | DHODH (0.55) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL4601100 | 0.86 | DHODH (0.56) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL5009870 | 0.82 | TACR3 (0.57) | TSHRPTGFRCYP3A4CYP2C19TACR3 | |
| SCHEMBL14009566 | 0.82 | TACR3 (0.60) | TSHRPTGFRCYP3A4CYP2C19TACR3 | |
| SCHEMBL4602735 | 0.81 | PDE10A (0.56) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL4601356 | 0.81 | TACR3 (0.77) | TSHRCYP3A4CYP2C19CYP2D6TACR3 | |
| SCHEMBL4601324 | 0.80 | TACR3 (0.57) | TSHRCYP3A4CYP2C19CYP2D6TACR3 | |
| SCHEMBL4602890 | 0.79 | PTGFR (0.52) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL14009573 | 0.78 | TACR3 (0.62) | PTGFRCYP3A4TACR3 | |
| SCHEMBL27669534 | 0.78 | DHODH (0.61) | PDE10ATSHRLMNAPOLBDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | claimed |
| EP-1915361-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007018466-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1915361-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018466-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ADORA3, KCNA3, TACR1 | PDE10A 1635/4885TSHR 228/4885LMNA 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.